ClinicalTrials.gg
RecruitingNCT07690059SensoryCloudUpdated Oct 14, 2026

A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough

A Phase 2 interventional study of SC0032 and Placebo in Refractory Chronic Cough and Unexplained Chronic Cough, sponsored by Sensory Cloud, Inc.. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Sensory Cloud, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 14, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Chronic Cough with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Chronic Cough · United Kingdom.

Planned enrollment
19th of 29
60 · median 100
Started
2026
with 2 others
Phase 2
15 of 36
2 open now
Registered
34th of 36
by date

Among the 36 studies in Chronic Cough with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2026, is one of 15 in phase 2, and was the 34th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

4 of the 36 studies in Chronic Cough with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Chronic Cough with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC

Read the detailed description

There are three parts to this study and an optional fourth part:

  1. an optional Usability Sub-Study,
  2. Part 1: Two Week Treatment (Run-In) Period,
  3. Part 2:Three Week Treatment (Parallel Arm) Period and
  4. Part 3: Four Week No Treatment (Follow-Up) Period, Participants completing the three primary parts of the study will attend four study visits. Participation in the optional Usability sub-study does not require any additional visits, see Figure 1. Trial Schema. Participants who do not meet criteria for Part 2, the Parallel Arm Period, at the end of Part 1, the Run-In period, will only be required to attend two study visits and will not receive an active treatment. Participants who discontinue the study prior to completion will be asked to complete an Early Termination Visit.
03

Conditions studied

  • Refractory Chronic Cough and Unexplained Chronic Cough

Browse trials for

Keywords

  • RCC
  • UCC
  • Refractory Chronic Cough
  • Unexplained Chronic Cough
  • SC0032
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females between 18 and 80 years.
  2. Capable of giving signed .
  3. Diagnosed with RCC (including unexplained chronic cough) for at least 6 months.
  4. At least 8 coughs per hour, 24-hour cough frequency during the 14-day Run-In Period.
  5. Score ≥ 40 mm on cough severity VAS at Screening.
  6. Normal /FVC ratio of greater than 70% at Screening
  7. A negative test for COVID-19.
  8. Women of and men must agree to use a highly effective method during the study and for at least 14 days after the last dose.
  9. Willing to carry study-related equipment as required for the study (e.g. cough monitor, phone).

Exclusion criteria

Exclusion Criteria:

  1. Current smoker/vaper (all forms of smoking and inhaled substances, including cannabis/tobacco smoke and nicotine vapours) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history.
  2. Diagnosis of (COPD), bronchiectasis, idiopathic pulmonary fibrosis, uncontrolled asthma or other serious pulmonary disease.
  3. Respiratory tract infection within 4 weeks before screening.
  4. History of in the last 5 years, unless it is a non-serious skin cancer.
  5. History of moderate or severe alcohol or drug use disorder within the last 3 years.
  6. Opioid use with in the 7 days prior to screening.
  7. History of a positive serologic test for virus surface antigen, or virus.
  8. Previous participation in a clinical trial in the last 30 days or 6-half half-lives of test drug activity.
  9. Current participation in or completion of speech language therapy intervention therapy for chronic cough within 8 weeks prior to screening.
  10. Use of Prohibited medications within 4 weeks prior to screening and at any time during the study: anti-tussive therapy, systemic , ACE inhibitors, opioids.
  11. Gabapentin and pregabalin are prohibited unless they are being administered for treatment of a condition other than RCC and have been on a stable dose of that medication for at least 6 weeks prior to screening and plan to remain on that dose for the duration of the study.
  12. Tricyclic antidepressants are prohibited unless they are being administered for treatment of a condition other than RCC and have been on a stable dose of that medication for at least 12 weeks prior to screening and plan to remain on that dose for the duration of the study.
  13. Beta blockers are prohibited unless they are on a stable dose for at least 6 weeks prior to screening.
  14. Use of dietary supplements containing magnesium for the duration of the study.
  15. History of myocardial infarction or other cardiac disorders as follows:

    • History of any of the following within 6 months prior to screening, myocardial infarction, stroke or , coronary revascularization (PCI or CABG), or heart failure.
    • History of arrhythmias, poorly controlled hypertension.
    • Any condition that, in the opinion of the investigator, places the participant at high risk for an acute cardiovascular event including but not limited to: angina symptomatic peripheral arterial disease, severe valvular heart disease, planned cardiovascular intervention or surgery during the study period, baseline >450 ms (men) or >470 ms (women), or any clinically significant abnormality as determined by the Investigator.
  16. History of any clinically significant or psychiatric condition that, in the eyes of the Investigator or designee, would not be suitable for this study. Or if, in the eyes of the Investigator or designee may prove non-compliant to study procedures.
  17. Spouses or other family members with a chronic cough in the household.
  18. Living and working in an excessively loud workplace (e.g. building site).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Sodium Chloride

    Device: Placebo

  • Experimental
    SC0032

    Magnesium Chloride

    Combination Product: SC0032

Interventions

  • Combination productSC0032

    Magnesium Chloride

  • DevicePlacebo

    Sodium Chloride

06

What researchers measure

Primary outcomes

  1. Difference in mean % change from baseline in 24-hour cough frequency using the mean of Days -8 to -2 for last 7 days of baseline vs the mean of Days 13-19 last 7 days of the treatment period, using the HYFE continuous cough monitor).

    Linear mixed model with log-transformed daily cough frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect

    Time frame: Day -8 to Day 19.

Secondary outcomes

  1. Time to onset of response based on median time (in days) from start of treatment to first day when mean treatment effect ≥30%, based on cumulative daily averages using the HYFE continuous cough monitor) from Day 1 to Day 20.

    Kaplan-Meier survival analysis to estimate median time to response (with 95% confidence intervals); log-rank test to compare response times of the treatment groups Cox proportional hazards model with adjustment for mean baseline cough frequency will yield a hazard ratio and 95% CIs.

    Time frame: From Day 1 to Day 20

  2. Determine duration of response (≥30% reduction relative to baseline) from baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).

    Linear mixed model with log-transformed daily cough frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect over the follow up period. The differences in the proportion of responders during each week of the follow up period will be evaluated using a Fisher's exact test.

    Time frame: Day -8 to Day 49

  3. Change in number of cough bouts per 24-hour period, defined using inter-cough gap thresholds of 2.0s, from Day -14 to -2 and Day 1 to Day 21.

    Linear mixed model with log-transformed daily bout frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect.

    Time frame: From Day -14 to Day 21

  4. Change in Leicester Cough questionnaire (LCQ) score on Day 0 vs Day 21. A 19-item, patient-completed health-related quality of life (HRQoL) for chronic cough. Each item is rated on a 7-point Likert scale (1-7), with higher score indicates better QoL.

    The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2 - Day 0) as a covariate and Treatment as the main factor; and a Baseline\*Treatment interaction term will be investigated. Type III sums of squares will be used. The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.

    Time frame: Day 0 to Day 21

  5. Change in Cough Severity Visual Analogue Scale (CS-VAS) score (0-100mm line anchored with "no cough" at 0 mm and "worst cough imaginable" at 100 mm) from Day 0 and Day 21.

    The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2) as a covariate and Treatment as the main factor; and a Baseline\*Treatment interaction term will be investigated. Type III sums of squares will be used. The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.

    Time frame: Day 0 to Day 21

  6. Change in Patient Global Impression of Severity 5-point score (PGI-S) score from Day 0 and Day 21. Response options typically range from "None" to "Severe", with higher scores indicating greater symptom severity.

    The distribution of PGI-S at Visit 3 (Day 21) between Placebo and SC0032 will be compared using a Cochran-Mantel-Haenszel test. An ordered (proportional odds) logistic regression model will be used to quantify treatment effects and estimate odds ratios (at Visit 3, adjusted for PGIS score at Visit 2 (Day 0) ) with 95% confidence intervals.

    Time frame: Day 0 to Day 21

  7. Change in categorical Patient Global Impression of Change (PGI-C) score from Day 0 and Day 21 analyzed as the proportion of participants achieving improvement on the 7-point scale. Response options range from "Very much improved" to "Very much worse."

    The difference in proportion of participants achieving improvement will be analysed using a Fisher's exact test (or CMH if appropriate). A binary logistic regression model (or ordinal equivalent) will be used to quantify treatment effects and estimate odds ratios with 95% confidence intervals.

    Time frame: Day 0 to Day 21

  8. Change in Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) score from Day 0 and Day 21. A 14-item tool measuring subjective laryngeal sensory symptoms. Items are rated on a 7-point Likert scale, with lower scores indicating greater severity.

    The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2) as a covariate and Treatment as the main factor; and a Baseline\*Treatment interaction term will be investigated. Type III sums of squares will be used. The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.

    Time frame: Day 0 to Day 21

  9. Change in mean daily cough from Day -8 to -2 vs Day 13-19 in Daily Cough Numeric Rating Scale (CS-NRS), an 11-point PRO rating severity of their cough over the past 24 hours. The scale ranges from 0 ("no cough") to 10 ("worst possible cough").

    Linear mixed model as per Item 1 (primary endpoint).

    Time frame: Day -8 to Day 19

  10. Report incidence of treatment-emergent adverse events (TEAEs).

    Descriptive summary of incidence of treatment-emergent adverse events by treatment according to SOC and Preferred Term; n (%) frequency for duration of study.

    Time frame: Day -14 to Day 49

  11. Report the severity of TEAEs.

    Descriptive summary of severity (number and % of mild, moderate, or severe) of treatment-emergent adverse events by treatment for duration of study according to SOC and Preferred Term; n (%) frequency.

    Time frame: Day -14 to Day 49

  12. Change from in FEV₁ and FVC from Day -14 to Day 49 by treatment group.

    Descriptive change distributions by treatment group.

    Time frame: Day -14 to Day 49

  13. Report number and % of participants with ≥1 serious adverse event (SAE) for duration of study.

    Descriptive summary by treatment according to SOC and Preferred Term; n (%) frequency.

    Time frame: Day -14 to Day 49

  14. Difference in mean % change from baseline in 24-hour cough frequency. The mean of Days -8 to -2 (baseline) vs the mean of Days 1-7 and 8-12 (Parallel Arm period).

    The same model used in the primary objective (Item 1) will be applied.

    Time frame: Day -8 to Day 12

  15. Determine the duration of response of SC0032 vs placebo by identifying the last week post-treatment when the mean treatment effect remains ≥20% reduction and ≥50% reduction.

    Difference in mean % change in cough frequency between Day 22-28, 29-35, 36-42, 43-49 (Follow-up Period) and mean % change in cough frequency for Day -8 to -2 (baseline), SC0032 vs placebo. Descriptive and inferential comparison (as per item 3; for ≥20% reduction and ≥50% reduction thresholds.

    Time frame: Day -8 to Day 49

  16. Define time to onset of effect based on cough bouts analyzed as per Objective 2 ((≥30% reduction), time course of treatment as per Objective 3 (baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).

    Time to onset will be analysed as per Objective 2, time course of treatment as per Objective 3 and the cough to bout ratio will be analysed using a linear mixed model (as per the primary).

    Time frame: Day -8 to Day 49

  17. Change in number, duration, and coughs per bout across definitions using linear mixed model with treatment group as a fixed effect, study day as a repeated-measure and random effects for participants between Day -14 to -2 and Day 1 to Day 21.

    Compare number, duration, and coughs per bout across definitions using linear mixed model with treatment group as a fixed effect, study day as a repeated-measure and random effects for participants.

    Time frame: Day -14 to Day 21

  18. Change in PRO's (CS-VAS, PGI-S, LCQ, LHQ) from Day -14 to Day 0 and Day 21 to Day 49.

    Descriptive summaries and change from Visit 1 (Day -14) to Visit 2 (Day 0) and from Visit 3 (Day 21) to Visit 4 (Day 49). All ANCOVAs as per Item 5. Except PGI-S which will be analyzed as per Item 7, along with descriptive summaries.

    Time frame: Day -14 to Day 49

  19. The proportion of participants with a clinically meaningful change in PGI-C at Visit 4 -Day 49.

    Descriptive summaries of actual values at Visit 4 (Day 49) by treatment group, as per Item 8.

    Time frame: Day -14 to Day 49

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.

Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jul 8, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Apr 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility U Floor, Belfast City Hospital is now Recruiting
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility U Floor, Belfast City Hospital is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07690059
Lead sponsor
Sensory Cloud, Inc.
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Jul 13, 2026
Primary completion
Jan 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion